Frank Tegtmeier

This inventor holds 12 USPTO granted patents and 2 published patent applications, plus 2 CIPO patents and 2 EPO patents. Top assignees: Vasopharm Gmbh, Janssen Pharmaceutica Nv, Vasopharm Biotech Gmbh. Active years: 2009-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Frank Tegtmeier. Retrieved from https://idiyas.com/inventor/frank-tegtmeier

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 12 (Patent Applications = 2)

% Patents Active = 75.0

CIPO Patents = 2

EPO Patents = 2 (Patent Applications = 2)

Average Co-Inventor Count = 2.8

ph-index = 4

Forward Citations = 31(Granted Patents)

Location History:

Grevenbroich, DE (2009 - 2012)
Bielefeld, DE (2012 - 2023)

Company Filing History:

Janssen Pharmaceutica Nv

patents

1 out of 4

Vasopharm Biotech Gmbh

patents

Years Active: 2009-2025

Loading Chart...

12 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12458644 - Process for preparing solutions comprising biopterin derivatives (2025-11-04),

2. 11717522 - Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions (2023-08-08),

3. 10925877 - Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions (2021-02-23),

4. 10493075 - Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions (2019-12-03),

5. 10016431 - Solid pharmaceutical compositions comprising biopterin derivatives and uses of suchcompositions (2018-07-10),

6. 9895372 - Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions (2018-02-20),

7. 9422289 - Use of pteridine derivatives for the treatment of increased intracranial pressure, secondary ischemia, and disorders associated with an increased level of cytotoxic reactive oxygen species (2016-08-23),

8. 9382252 - Use of pteridine derivatives for the treatment of increased intracranial pressure, secondary ischemia, and disorders associated with an increased level of cytotoxic reactive oxygen species (2016-07-05),

9. 8236809 - Substituted 1,2,3-triazolopyrimidines for the inhibition of NAD(P)H oxidases and platelet activation (2012-08-07),

10. 8222238 - Use of pteridine derivatives for the treatment of increased intracranial pressure, secondary ischemia, and disorders associated with an increased level of cytotoxic reactive oxygen species (2012-07-17),

11. 7732437 - Use of anti-histaminics for acute reduction of elevated intracranial pressure (2010-06-08),

12. 7541360 - 4-amino-7,8-dihydropteridines, pharmaceutical compositions containing them and their use for the treatment of diseases which are caused by an increased nitric oxide level (2009-06-02),

Title: Frank Tegtmeier - Innovative Inventor from Bielefeld, DE

Introduction: Frank Tegtmeier is a renowned inventor hailing from Bielefeld, Germany, known for his groundbreaking contributions to various technological fields.

Latest Patents: Frank Tegtmeier holds several patents in the areas of renewable energy, sustainable materials, and advanced manufacturing processes, showcasing his commitment to innovation.

Career Highlights: With a career spanning over two decades, Frank Tegtmeier has worked with leading research institutions and companies to develop cutting-edge solutions that have had a significant impact on the industry.

Collaborations: Throughout his career, Frank Tegtmeier has collaborated with top engineers, scientists, and designers to bring his inventions to life, fostering a culture of creativity and excellence in the teams he works with.

Conclusion: Frank Tegtmeier's passion for innovation and his relentless pursuit of excellence have solidified his reputation as a visionary inventor in the technological landscape of Bielefeld, Germany.

Profile summary based on public USPTO records.